Article
Identification of pathways to high-level vancomycin resistance in Clostridioides difficile that incur high fitness costs in key pathogenicity traits.
PLoS biology - 1 Aug 2024
Buddle Jessica E, Thompson Lucy M, Williams Anne S, Wright Rosanna C T, Durham William M, Turner Claire E, Chaudhuri Roy R, Brockhurst Michael A, Fagan Robert P
Abstract excerpt
Clostridioides difficile is an important human pathogen, for which there are very limited treatment options, primarily the glycopeptide antibiotic vancomycin. In recent years, vancomycin resistance has emerged as a serious problem in several gram-positive pathogens, but high-level resistance has yet to be reported for C. difficile, although it is not known if this is due to constraints upon resistance evolution...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
